Home 2023

Regeneron

StockWatch: Regeneron’s All Ears for Hearing Loss Drug Developer
Drug Discovery

StockWatch: Regeneron’s All Ears for Hearing Loss Drug Developer

Alex Philippidis -
0
Effective IoT Infrastructure Critical for Digital Drug Firms
Bioprocessing

Effective IoT Infrastructure Critical for Digital Drug Firms

John Sterling -
0
Top 25 Biotech Companies of 2023
A-Lists

Top 25 Biotech Companies of 2023

Alex Philippidis -
20
Molecular Scissors Are Making the Cut … in Clinical Trials
Genome Editing

Molecular Scissors Are Making the Cut … in Clinical Trials

Kathy Vuksanaj -
0
StockWatch: COPD Data, Analysts, Treg Cell Therapy Deal Lift Regeneron
GEN Edge

StockWatch: COPD Data, Analysts, Treg Cell Therapy Deal Lift Regeneron

Alex Philippidis -
0
Double Dare: Exscientia Expands AI Platform into Antibody Design
Artificial Intelligence

Double Dare: Exscientia Expands AI Platform into Antibody Design

Alex Philippidis -
0
Supreme Court Grapples with the Enablement Standard for Functional Genus Patent Claims
GEN Edge

Supreme Court Grapples with the Enablement Standard for Functional Genus Patent Claims

Alex Philippidis -
0
StockWatch: Investors Weigh Genome Editing after Clinical Hold, Patient Death
Cancer

StockWatch: Investors Weigh Genome Editing after Clinical Hold, Patient Death

Alex Philippidis -
0
New Labs, New Funds: Activity Blossoms in the Leading U.S. Biopharma Clusters
Insights

New Labs, New Funds: Activity Blossoms in the Leading U.S. Biopharma Clusters

Alex Philippidis -
0
123...11Page 1 of 11
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.